




SWhere is the common sense in aortic valve replacement? A review of
hemodynamics and sizing of stented tissue valvesTorsten Doenst, MD, PhD,a Paulo A. Amorim, MD,b Nidal Al-Alam, MD,d Sven Lehmann, MD,b
Chirojit Mukherjee, MD,c and Gloria Faerber, MDaHeated debates revolve around the hemodynamic performance of stented aortic tissue valves. Because the opening area
strongly influences the generation of a pressure gradient over the prosthesis, and the outer diameter determines which valve
actually fits into the aortic root, it would seem logical that the valve with the greatest opening area in relation to its outer
diameter should allow the best hemodynamic performance. Interestingly, neither of these 2 parameters is reflected by the
manufacturing companies’ size labels or suggested sizing strategies. In addition, it is known that valves with the same
size label from different companies may differ significantly in their actual dimension (outer diameter). Finally, the
manufacturer-suggested sizing strategies differ so much that expected differences from valve design may get lost because
of differences in sizing. These size and sizing differences and the lack of information on the geometric opening area com-
plicate true hemodynamic comparisons significantly. Furthermore, some fluid dynamic considerations regarding the deter-
mination of opening area by echocardiography (the effective orifice area) introduce additional obscuring factors in the
attempt to compare hemodynamic performance data of different stented tissue valves. We analyzed the true dimensions
of different tissue prostheses and the manufacturer-suggested sizing strategies in relation to published effective orifice areas.
We have demonstrated how sizing and implantation strategy have much greater impact on postoperative valve hemodynam-
ics than valve brand or type. In addition, our findings may explain the different opinions regarding valve hemodynamics of
different tissue valves. (J Thorac Cardiovasc Surg 2011;142:1180-7)The need to replace an aortic valve always raises the question
of valve choice (mechanical or tissue), with a recent trend to-
ward the preferred use of stented tissue valves in the great
majority of cases.1 Tissue valves, however, have shorter
long-term durability and also have smaller aortic valve open-
ing area than do mechanical valves.2,3 These facts initiated
a series of investigations comparing durability and
hemodynamics of tissue valves. Interestingly, the
hemodynamic comparisons have taken on an enormous
perplexity because valve sizers, the valves themselves, and
the manufacturers’ size labeling and suggested sizing
strategies are inconsistent. As a result, comparing
hemodynamics among tissue valves today is similar to
comparing apples to oranges.
Asearly as1987,Bonchekandcolleagues4described adis-
crepancy between the true size and the nominal size of me-
chanical aortic valve sizers. This analysis was followed by
several other descriptions of valve size and valve labeling in-
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1180 The Journal of Thoracic and Cardiovascular Sura confusing myriad of valves with different dimensions,
nominal sizes, and sizing strategies. In this analysis, we
comprehensively review the true dimensions of tissue
prostheses together with the manufacturer-suggested sizing
strategies and relate them to their hemodynamic perfor-
mance (effective orifice area [EOA] and pressure gradients).
We conclude that sizing and implantation technique have
amuchgreater impact onpostoperativevalve hemodynamics
than valve brand or type. The rationale behind this conclu-
sion requires a short review of some basics on valve sizes
and sizing as well as of the echocardiographic determination
of the aortic valve opening area, which are given in the fol-
lowing sections.PROSTHESIS WITH THE SAME SIZE LABEL
DIFFER SIGNIFICANTLY IN THEIR OUTER
DIAMETER
Table 1 shows the outer diameters of the most commonly
implanted tissue valve prostheses relative to their manufac-
turers’ size labels and the diameters of their corresponding
sizers. Figure 1 shows representative pictures of these
valves together with their specific sizers. The values for
the valves’ outer diameters were obtained from the ‘‘small
print’’ of the original packages of the valves. Companies
are required to provide this information to obtain US
Food and Drug Administration approval or Conformite
Europeene (CE) marking. The dimensions of the sizers
were measured by us with a caliper.
The valve with the smallest outer diameter for a given
size label is the Mitroflow (Sorin SpA, Milan, Italy) and
the ones with the greatest outer diameters are the Perimountgery c November 2011
Abbreviations and Acronyms
EOA ¼ effective orifice area
GOA ¼ geometric orifice area
LVOT ¼ left ventricular outflow tract




S(Carpentier-Edwards Perimount model 2900; Edwards
Lifesciences Corp, Irvine, Calif) for smaller sizes and the
Mosaic (Mosaic aortic valve model 305; Medtronic, Inc,
Minneapolis, Minn) for larger sizes. It is important to
note that (1) none of the valves outer dimension corresponds
to the size label and (2) there is great variability among the
different manufacturers. One reason for the mismatch of
outer diameter to size label and the great variability may
be the fact that the label is derived from the inner diameters
of the valves’ stents. The variability would then originate
from differences in sewing ring and stent designs. Christa-
kis and associates,8 however, demonstrated before that
even the inner diameters differ significantly and do not al-
ways match the size label. Irrespective of the labeling, the
outer diameter is key for implantation of the valve into
the aortic root. From a commonsense perspective, the outer
diameter should determine the maximal size of a valve that
can be implanted. Inspecting Table 1 would then suggest
that if a size 21 Perimount can be implanted, a size 23 Ma-
gna (Magna, Carpentier-Edwards Perimount Magna model
3000; Edwards Lifesciences), size 25 Mitroflow, or size 25
Epic (Epic Aortic; St Jude Medical, Inc, St Paul, Minn)
should also fit (their outer diameters are all 28 or 29 mm).
This reasoning is intriguing and will be addressed in more
detail.VALVE-SPECIFIC SIZERS ARE NOTALWAYS
METRIC AND DIFFER AMONG
MANUFACTURERS
The sizer dimensions are also not uniform. Whereas the
Perimount and Epic sizers are metric and reflect the size la-
bel, the true diameters of the other sizers differ significantly
from their labels. In case of the Epic Supra (St Jude Medi-
cal) and the Magna, this deviation is understandable, be-
cause the sizer is a valve replica and the sizing strategy is
based in the position of the valve in the aortic root, and
the base model sizer is only used to get a ‘‘first size impres-
sion.’’ For the Mosaic and the Mitroflow, the suggested siz-
ing strategies are comparable to those of the Perimount or
the Epic (based on sizing the dimension of the left ventric-
ular outflow tract [LVOT]); however, the dimensions of the
sizers are either 2 to 3 mm greater (Mitroflow) or smaller
(Mosaic) than their labels. The result is the selection of
valves with different size labels for the same patient when
using the Perimount or Epic on the one hand or the Mitro-
flow or Mosaic on the other (Figure 2, C). InspectingThe Journal of Thoracic and CarTable 1 would then suggest that if a 23 Perimount sizer re-
flects the appropriate size, a 25Mosaic sizer and a 21Mitro-
flow sizer should fit the same. Thus for the same patient
a size 23 Perimount, a size 25 Mosaic, or a size 21 Mitro-
flow would be selected according to the manufacturer-
suggested sizing strategy.
To summarize the information in Table 1, valve size se-
lection is misleading because the sizers differ in their di-
mensions, and comparisons of hemodynamic performance
is confusing because valves with different size labels would
be selected for the same patient. In addition, the valves dif-
fer in their outer dimensions (their true size; Table 1). Thus
hemodynamic comparisons according to manufacturer size
label are inappropriate and inadvertently lead to erroneous
conclusions.
Figure 2 illustrates this confusion by comparing the sizer
dimensions to the valves’ outer diameters and the mean
EOAs published for each size in the literature. The source
references are listed in the figure legend, and Table 2 lists
all the studies used for this analysis along with their values.
The relationship of mean EOAs to the size labels (Figure 2,
A) gives a completely different impression of the individual
valve area than does the relationships of EOAs to the outer
diameter (Figure 2, B). The impression is again changed if
one compares the EOAs determined for the different valves
as they would be selected by the manufacturer-suggested
sizing strategies (Figure 2, C). The comparison in
Figure 2, C, probably reflects ‘‘real life’’ most accurately.
Inspecting this figure more closely reveals that the hemody-
namic performance (as judged by the EOA) is similar for
most of the different manufacturers. Two valves, however,
appear to perform worse (the Epic and the Mitroflow). We
illustrate further here that this clinically relevant poor per-
formance of these valves is, however, not due to valve
design.
IMPLANTATION TECHNIQUE AND SIZING
STRATEGIES SIGNIFICANTLYAFFECT
PRESSURE GRADIENTS AND AORTIC VALVE
AREAS AS MEASURED BY
ECHOCARDIOGRAPHY
Echocardiography is the main diagnostic tool for the as-
sessment of preoperative and postoperative pressure gradi-
ents and aortic valve area. The aortic valve area is mostly
obtained from the continuity equation and relies on the as-
sessment of flow velocity over the prosthesis and the dimen-
sion of the LVOT. The greater the difference between the
dimension of the LVOT and the aortic valve area, the
more the bloodstream will be compressed when passing
through the opening. The site of maximal compression of
the bloodstream is termed the vena contracta. The continu-
ity equation states that the product of the flow velocity and
the area of the LVOT equals the same product at the vena
contracta. Thus flow velocity increases as the bloodstreamdiovascular Surgery c Volume 142, Number 5 1181
TABLE 1. External diameters of the most commonly implanted aortic
tissue prostheses and their corresponding sizers, as shown in Figure 1
External diameter (mm)
Size label Epic Supra Mosaic Perimount Magna Mitroflow
Valves
19 — 25 25 26 24 21
21 25 27 27 29 26 24
23 27 29 30 31 28 26
25 29 31 33 33 30 28
27 31 33 36 35 32 32
Sizers
19 — 25 17 19 23 21
21 21 27 18.5 21 25 23
23 23 29 20.5 23 27 26
25 25 31 22.5 25 28.7 28
27 27 33 24 27 31 31
Epic, Epic Aortic St Jude Medical, Inc, St Paul, Minn; Supra, Epic Supra; St Jude
Medical; Mosaic, Mosaic aortic valve model 305; Medtronic, Inc, Minneapolis,
Minn; Perimount, Carpentier-Edwards Perimount model 2900; Edwards Lifescien-
ces, Corp, Irvine, Calif; Magna, Carpentier-Edwards Perimount Magna model
3000; Edwards Lifesciences; Mitroflow, Mitroflow; Sorin SpA, Milan, Italy.




Sis compressed. The EOA is the cross-sectional area of the
compressed bloodstream at the level of the vena contracta
(see Garcia and Kadem9 for a detailed review).
Although the EOA reflects a functionally relevant param-
eter for the patient, it is often taken as measure of the aortic
valve area.10-12 This assumption is inappropriate, because it
may lead to the conclusion that EOA is identical to the
geometric orifice area (GOA). As Figure 3 schematically il-
lustrates, however, the EOA may (ideally) but does not nec-
essarily have to equal the GOA. The importance of this
difference becomes clear with the following example. Con-
sider A and B, 2 different patients with 2 different anato-
mies (1 with wide LVOT and aorta, Figure 3, A, and theFIGURE 1. Representative photographs of 6 stented tissue valves used for the
a valve size is based on fitting the sizer in the left ventricular outflow tract. In the
valve in the aortic root after the base sizer has been used. Epic, Epic Aortic St Jud
Mosaic aortic valve model 305; Medtronic, Inc, Minneapolis, Minn; Perimount
Irvine, Calif; Magna, Carpentier-Edwards Perimount Magna model 3000; Edw
1182 The Journal of Thoracic and Cardiovascular Surother with slim LVOT and aorta, Figure 3, B). Implantation
of the identical valve into these 2 patients (which can be
achieved by different positioning and sizing) results in dif-
ferent EOAs as assessed by echocardiography, although the
GOAs are identical. Thus taking EOA as a measure of valve
area is incorrect. The GOA should be referred to for inter-
valve comparisons. It is practically impossible, however,
to find published assessments of the true GOAs of the valves
(most values are inappropriately based on calculating the
inner stent area assuming that the valves open com-
pletely13-15 rather than on planimetric measurements of
the open orifice). Yet the GOA is critical to assess the
hemodynamic properties of a valve because it can be
related to the outer diameter of the valve or stent. This
relationship would make different valves directly
comparable with respect to their hemodynamic potential
independent of implantation technique, whereas assessing
EOA provides information on functional relevance of an
implanted valve in an individual patient. It is possible,
however, that because of different construction methods
different valves may not open fully under given flow
conditions and that GOAs may vary for the same valve
depending on flow and pressure conditions. From our
perspective, a range of GOAs could then be given for
such a valve, because the principal importance of this
value for hemodynamic performance of the prosthesis and
the generation of the individual EOA remains the same.
These considerations suggest that (1) trying to compare
prosthetic valve areas on the basis of EOA determination
is inappropriate, and (2) surgical technique, including siz-
ing, may have a greater influence on postoperative hemody-
namics than the selection of a specific valve type. Indeed,
the literature provides convincing evidence for this conclu-
sion. Figure 4 shows the average published EOAs for theanalyses in this article (A) and their corresponding sizers (B). Selection of
cases of Supra andMagna, a valve replica is used to assess placement of the
eMedical, Inc, St Paul, Minn; Supra, Epic Supra; St JudeMedical;Mosaic,
, Carpentier-Edwards Perimount model 2900; Edwards Lifesciences Corp,
ards Lifesciences; Mitroflow, Mitroflow; Sorin SpA, Milan, Italy.
gery c November 2011
FIGURE 2. Comparison of sizer dimension (open bars), outer diameter
(hatched bars), and average published effective orifice area (EOA, filled
bars) values among 6 commonly implanted stented aortic tissue valves
shown in Figure 1. A, Comparisons based on manufacturers’ size labels.
B, Comparisons based on outer diameters. C, Comparisons based on sizing
strategy as suggested by themanufacturer with the sizers shown in Figure 1.
Sizers are for sizing the outflow tract dimension (Epic, Mosaic, Perimount,
Mitroflow) or for the supra-annular position of the valve (Supra, Magna).
Values for effective orifice area were calculated as the mean value of pub-
lished data from the following references: Epic,17 Supra,18 Mosaic,19-21
Perimount,17,19,20,22-30 Magna,16,31,32 and Mitroflow.33-35 The original
values are listed in Table 2, and manufacturer values are not included.




SEpic and the Epic Supra valves, as well as the Perimount
and the Magna valves (Table 2 and Figure 4 give source ref-
erences). We used sizes 21 and 23 for this illustration, be-
cause these are the most frequently implanted valveThe Journal of Thoracic and Carsizes.16 Both St Jude Medical and Edwards Lifesciences
have modified the sewing rings of their base models (Epic
and Perimount, respectively) without actually altering the
valve and the stent on which it is mounted. Thus the actual
valve apparatus of the size 23 Epic is identical to that of the
size 21 Epic Supra. Because of the different sizing strategy
(the use of a replica is recommended), a larger stent (and
thereby valve) can be implanted in the same patient. In
the case of the Perimount andMagna prostheses, the sewing
ring was tapered so that the Magna is still labeled the same,
but the outer diameter is roughly 3 mm slimmer for a given
size (Table 1). Because theMagna also comeswith a replica,
a size 23 Magna can often be implanted in a root that would
fit a size 21 Perimount. Similar modifications were done on
the Mosaic to generate the Mosaic Ultra (Medtronic), with
a slimmer outer diameter; however, the published EOAs are
not size specific for the Mosaic Ultra and are therefore not
illustrated.
The comparisons in Figure 4 illustrate with ‘‘real life’’
data the fluid dynamic relevance of these modifications
for echocardiographic EOA determination. In both cases,
the new (next generation) valve results in the determination
of greater echocardiographic EOAs. In other words, al-
though the valve apparatuses of both the two St Jude Med-
ical valves and the two Edwards valves are geometrically
identical (specifically in GOA), the EOAs as determined
by echocardiography are substantially greater in the ‘‘next
generation’’ valves (Epic Supra and Magna, respectively).
These results support the conclusion that the difference in
assessed opening area is due to the described fluid dynamic
effect, which in turn is based on the implantation of the
greater valve relative to the LVOT in the next generation
valves relative to the base model. Therefore differences in
valve stent or leaflet design seem to be less important.
DIFFERENCES IN FLUID DYNAMIC EFFECTS
AND SIZING STRATEGIES EXPLAIN
DIFFERENCES IN OPINION ON TISSUE VALVE
HEMODYNAMICS
The illustrated fluid dynamic effects, together with dif-
ferences in the ‘‘aggressiveness’’ of manufacturer-
suggested sizing strategies, may also explain the different
opinions on individual valve hemodynamics. Inspection
of Table 1 reveals that the outer diameter of the size 21
Epic is 2 mm smaller than that of the size 21 Mosaic.
The differences in sizing strategies, however, result in
the implantation of even a size 23 Mosaic valve (outer di-
ameter 30 mm) in a patient for whom a size 21 Epic (outer
diameter 25 mm) would be chosen (both sizers are 21
mm). The same effect can be found when comparing
Epic and Perimount. In that case, the sizers are identical
but the outer diameter of the Perimount (29 mm) is signif-
icantly larger than that of the Epic (25 mm), resulting in
the implantation of the bigger valve when selecting thediovascular Surgery c Volume 142, Number 5 1183
TABLE 2. Reference sources for published effective orifice areas and calculations of mean effective orifice area used for comparisons of valves
shown in Figure 1
Manufacturer labeled valve size
Effective orifice area (cm2) 19 21 23 25 27
Epic
Goetzenich et al17 — 0.8 1.0 1.2 2.2
Supra
Sakwa et al18 1.5 1.6 1.7 — —
Mosaic
Eichinger et al19 0.8 1.4 1.6 2.4 2.2
Seitelberger et al20 — 1.3 1.6 1.7 2.2
Dalmau et al21 1.3 1.4 1.7 1.8 2.1
Mean  SD 1.4  0.4 1.4  0.1 1.6  0.0 1.9  0.4 2.1  0.1
Perimount
Eichinger et al19 1.0 1.4 1.9 2.1 2.1
Maslow et al23 1.0 1.4 1.9 2.6 3.1
Botzenhardt et al24 1.0 1.4 1.9 2.1 —
McDonald et al25 1.2 1.5 1.8 — —
Aupart et al26 1.1 1.3 1.4 1.5 2.2
Aupart et al27 1.1 1.4 1.7 1.9 —
Seitelberger et al20 1.3 1.4 1.7 1.8 2.2
Rao et al22 1.3 1.5 1.8 2.0 2.1
Goetzenich et al17 — 1.2 1.4 1.6 1.4
Banbury et al28 0.8 1.0 1.2 1.1 —
Takakura et al29 1.6 — — — —
Dellgren et al30 1.0 1.1 1.5 1.4 1.6
Mean  SD 1.1  0.2 1.3  0.2 1.6  0.2 1.8  0.4 2.1  0.5
Magna
Borger et al31 1.2 1.3 1.4 1.4 1.6
Dalmau et al16 1.4 1.8 2.2 2.4 2.0
Botzenhardt et al32 1.7 1.7 2.5 2.3 —
Mean  SD 1.4  0.3 1.6  0.3 2.0  0.6 2.0  0.5 1.8  0.3
Mitroflow
Tasca et al33 1.2 1.4 1.6 — —
Bleiziffer et al34 1.0 1.4 1.6 2.0 2.4
Garcıa-Bengochea et al35 1.1 1.3 1.5 1.8 —
Mean  SD 1.1  0.1 1.4  0.1 1.6  0.1 1.9  0.2 —
Epic, Epic Aortic St Jude Medical, Inc, St Paul, Minn; Supra, Epic Supra; St Jude Medical; Mosaic, Mosaic aortic valve model 305; Medtronic, Inc, Minneapolis, Minn; Peri-
mount, Carpentier-Edwards Perimount model 2900; Edwards Lifesciences Corp, Irvine, Calif;Magna, Carpentier-Edwards Perimount Magna model 3000; Edwards Lifescien-
ces; Mitroflow, Mitroflow; Sorin SpA, Milan, Italy.




SPerimount. Thus the impression may arise that the Epic
may be hemodynamically inferior. It is not the valve, how-
ever, but the sizing strategy and implantation technique
that cause the implantation of prostheses with different ac-
tual dimensions and therefore allow us to arrive at this con-
clusion. Thus the question whether these valves actually
display true differences in hemodynamic properties cannot
be answered at this time.
An example for an erroneous assumption of the hemody-
namic superiority of a specific tissue valve can be found for
instance by comparing the Mitroflow with the Mosaic. The
Mitroflow has been designed for improved hemodynamic
performance. The pericardial cusps of the valve are wrap-
ped around the stent and therefore providemore valve open-
ing in relation to the outer diameter of the prosthesis than do1184 The Journal of Thoracic and Cardiovascular Surother valves. The majority of this hemodynamic advantage
by design, however, is lost by a ‘‘defensive’’ sizing strategy.
An aortic root that is sized to host a size 19 Mitroflow will
result in the selection of a size 23 Mosaic according to the
Medtronic sizing strategy (both sizers have a diameter of
21 mm). The size 23 Mosaic, however, has an outer diame-
ter that is 9 mm larger than that of the Mitroflow (Table 1).
Thus the design advantage of the Mitroflow is overcome by
the Mosaic (according to manufacturer size comparisons)
through the placement of a larger valve selected by a differ-
ent sizing strategy. It is very likely that the actual GOA of
the size 23 Mosaic is the same as or even bigger than that
of the size 19 Mitroflow. Again, actual values for GOA
are not available, but the average EOAs found in the litera-
ture for these prostheses indirectly support our conclusiongery c November 2011
FIGURE 3. Idealized illustration of the influence of valve position and re-
lationship between geometric orifice area (green) and left ventricular out-
flow tract on the determination of the effective orifice area (red) by
echocardiography. A, If a tissue valve leaves a rest stenosis after replace-
ment, the size of maximal bloodstream contraction (vena contracta) moves
distally to the geometric valve opening. As a consequence, effective orifice
area underestimates geometric orifice area. B, Ideal hemodynamic place-
ment of the same tissue valve would place the vena contracta at the site
of the geometric orifice area of the tissue valve, and effective orifice area









































FIGURE 4. Comparisons of published effective orifice area (EOA) values
from the size 23 Epic and the size 21 Epic Supra prostheses (A) and the
Perimount and Perimount Magna prostheses (B). Note that in both A and
B the 2 prostheses compared have geometrically identical stent design
and differ only in the sewing ring (see Figure 1 for valve designs and
Table 2 for the source references).




S(Figure 2, C). Here the Mosaic is even seen to have a greater
EOA than the Mitroflow.SUPRA-ANNULAR AND INTRA-ANNULAR
PLACEMENT OFA PROSTHESIS IS DETERMINED
BY THE SURGEON AND NOT BY STENT DESIGN
The conclusion that sizing and implant strategy signifi-
cantly affects the hemodynamic performance of a tissue
valve prosthesis requires addressing surgical technique.
The bulging shape of the aortic root allows the implantation
of a tissue valve into the root above the actual annulus. This
supra-annular placement requires sutures to be placed from
underneath the aortic annulus to the aortic root above the an-
nulus (Figure 5, A). If the stitching direction is reversed, and
the sutures exit the tissue inside the LVOT, the valve re-
ceives an intra-annular position (Figure 5, B). Industry has
taken this terminology to design specific valves for supra-,
intra-, or even supraintra-annular placement. It is important
to realize, however, that the exit point of the sutures below,
above, or even in the aortic annulus determines the final po-
sition of the prostheses, a condition that is relatively inde-
pendent of stent design (Figure 5, A and B). It is also
important to realize that the supra-annular placement of
a tissue prosthesis does not automatically result in superiorThe Journal of Thoracic and Carhemodynamics. Figure 5 also illustrates this statement. In-
arguably, an intra-annular placement of a tissue valve al-
ways results in loss of possible valve opening by placing
the sewing ring inside the LVOT (Figure 5, C). Supra-
annular placement allows placement of the inner margin
of the stent (the prosthetic valve itself) over the annulus
by ‘‘hiding’’ the sewing ring in the aortic root (Figure 3
and Figure 5, A). If a defensive sizing strategy is selected
or a smaller valve size is selected by the surgeon for one rea-
son or another, however, hemodynamics may be poor de-
spite supra-annular placement of the prosthesis because
the LVOT may become tapered down (Figure 5, D).WHAT SHOULD BE CHANGED FOR EVERYDAY
PRACTICE OF STENTED TISSUE VALVE
REPLACEMENT?
There are several objectives that need to be met by those
who are involved in the treatment and care of patients re-
quiring aortic tissue valve replacement. The first step is
the recognition of these phenomena and full comprehension
of the topic to be able to put echocardiographically deter-
mined values for EOA and pressure gradients into perspec-
tive. These data are relevant for the patient but cannot bediovascular Surgery c Volume 142, Number 5 1185
FIGURE 5. Schematic demonstration of supra-annular (A) and intra-
annular (B) placements of a valve prosthesis (violet) based on stitching di-
rection as well as illustration of intra-annular (C) or supra-annular (D)
placement of the same size tissue valve. Note that supra-annular placement
does not confer the expected hemodynamic benefit if the chosen valve is
too small, because it will result in tapering of the aortic annulus (eg,
with a defensive sizing strategy). Red ring, Effective orifice area; green
ring, geometric orifice area.




Sused to compare hemodynamic properties of different
stented tissue valves. For that, parameters independent of
individual anatomy are required (such as the GOA and the
outer diameter of the prosthesis). Second, industry would
help the surgeon to implant the biggest size possible by pro-
viding true valve replicas for optimal sizing (as is beginning
to be the case with the newer generation tissue valves, the
Epic Supra, the Perimount Magna Ease [Edwards1186 The Journal of Thoracic and Cardiovascular SurLifesciences], the Mosaic Ultra, and the brand new Trifecta
[St Jude Medical]). Third, surgeons should continue to im-
prove the ability to implant large prostheses by assessing
aortic root geometry, applying valve replicas, and respect-
ing geometric differences between patient and prosthesis
commissures when implanting the valve. Finally, presenting
the GOAs of the individual prostheses would allow sur-
geons, cardiologists, and anesthesiologists to compare the
determined EOA with the GOA. This information would
give an impression about the hemodynamic quality of valve
placement. The closer the EOA is to the GOA, the hemody-
namically better the valve is positioned in the root. This
simple comparison might be an extremely valuable tool to
determine the hemodynamic relevance of an aortic valve
prosthesis and its relation to the way it is implanted. Issues
such as angulation of the prosthesis in the aortic root, as
well as the angle between the LVOT axis and the axis of
the ascending aorta, affect fluid dynamics and energy loss
(not specifically addressed in this article). All these influ-
ences would be considered by comparing the individual
EOA of the patient with the GOA of the prosthesis.CONCLUSIONS
Here we present evidence emphasizing how lack of uni-
formity in tissue valve size and sizer specifications makes
proper hemodynamic comparisons among different tissue
valves difficult and misleading. We highlight the concept
that a geometric implantation technique together with
replica-based valve sizing might yield optimal hemody-
namic outcome which may be easily assessed by relating
EOA and GOA. Finally, we conclude that for the currently
available stented tissue valves, surgical implantation tech-
nique and the current sizing strategies are together greater
determinants of postoperative hemodynamic performance
than valve type, brand, or design.
We thank Tirone David, MD, for many helpful discussions,
valuable advice, and inspiration for finding the right article title.References
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